Therapeutic Advances to Treat Resistant Gram-Negative Bacteria

1.50 CME
1.50 CME with ABIM MOC
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Therapeutic Advances to Treat Resistant Gram-Negative Bacteria


Provider Statement

This continuing education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.

Activity Description

Carbapenem antibiotics have an important antibiotic niche in that they retain activity against the chromosomal cephalosporinases and extended-spectrum beta-lactamases found in many gram-negative pathogens. The emergence of carbapenem-hydrolyzing beta-lactamases has threatened the clinical utility of this antibiotic class and brings clinicians a step closer to the challenge of “extreme drug resistance” in gram-negative bacilli. Clinically available potent antibiotics that are active against gram-negative pathogens such as carbapenem-resistant pathogens are becoming increasingly scarce in the present era of antibiotic resistance. However, the recent inclusion of new therapies for gram-negative, carbapenem-resistant infections in the treatment armamentarium have provided new tools for treating clinicians. This podcast series will review the prevalence and burden of carbapenem-resistant gram-negative bacterial infections, the current and emerging treatment options for these infections, and the impact of COVID-19 on antibiotic stewardship.

Target Audience

The intended audience for this activity is infectious disease specialists, gastroenterologists, critical care physicians, hospitalists, pulmonologists, hospital pharmacists, and other health care professionals involved in the management of patients with carbapenem-resistant bacteria infections.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine the prevalence, patterns, and mechanisms of carbapenem-resistant, gram-negative bacterial infections, including the challenges involved in treating them.
  • Identify the burden of hospital-acquired pneumonia, ventilator-associated pneumonia, urinary tract infections, and intra-abdominal infections in patients infected with resistant gram-negative-pathogens, including carbapenem-resistant pathogens.
  • Review current and emerging treatment options to treat gram-negative bacterial infections, such as carbapenem-resistant infections.
  • Assess the impact of COVID-19 on antibiotic stewardship and the potential clinical implications.

Activity Chair

Marin H. Kollef, MD
Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine
Professor of Medicine
Division of Pulmonary & Critical Care Medicine
Washington University School of Medicine
Director, Critical Care Research
Director, Respiratory Care Services
Barnes‐Jewish Hospital
St. Louis, MO


M. Cristina Vazquez Guillamet, MD
Assistant Professor of Medicine
John T. Milliken Department of Internal Medicine- Division of Infectious Diseases
Washington University School of Medicine
St. Louis, MO

James Lewis, PharmD, FIDSA
ID Pharmacy Supervisor & Associate Professor
Oregon Health & Science University
Departments of Pharmacy & Infectious Diseases
Portland, OR

Jason M. Pogue, PharmD, FCCP, BCIDP
Clinical Professor, Infectious Diseases
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.50 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-22-021-H01-P, effective 6/20/2022. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, June 20, 2022, to June 19, 2023.

How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or Statement of Continuing Pharmacy Education Credit.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.


Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant relationship(s)

M. Cristina Vazquez Guillamet, MD
No relevant financial relationships to disclose.

Marin H. Kollef, MD
Advisor: Merck, Pfizer, Shionogi
Consultant: Merck, Pfizer, Shionogi

James Lewis, PharmD, FIDSA
Consultant: Cidara, Merck

Jason M. Pogue, PharmD, FCCP, BCIDP
Consultant: Entasis, GlaxoSmithKline, Melinta, Merck, Qpex, Shionogi, Spero, Utility

Reviewers report the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP; and Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at